Josh Bilenker | GenomeWeb

Josh Bilenker

Mar 19, 2015

Josh Bilenker has resigned from Roka Bioscience's board, citing demands on his time and other professional commitments. His resignation is effective immediately. Bilenker, who is the CEO of and a director at Loxo Oncology, joined Roka's board in early 2012 and served on its audit committee.

More Like This

Jan 18, 2017

Mary Duseau, Paul Thomas

Roka Biosciences, a manufacturer of molecular diagnostics for foodborne pathogens, has named Mary Duseau as president and CEO. She succeeds Paul Thomas, who held those posts since 2009 and will now serve as chairman of the firm's board of directors. Duseau has been senior vice-president and chief commercial officer at Roka since 2015. She was previously global sales director at Andor Technologies, a division of Oxford Instruments, and held various sales and management positions at PerkinElmer between 2000 and 2012. 

Jan 17, 2017

James Lewis

James Lewis has joined cancer genome testing firm Personal Genome Diagnostics as senior vice president of corporate development. He will oversee strategic planning, collaboration initiatives, and fundraising activities directed at securing capital to meet corporate objectives, including a planned Series B financing round this year. Lewis was previously VP of business development at Esperance Pharmaceuticals. Before that, he was at AstraZeneca where he led business development work for the cardiovascular franchise and was on the Crestor commercial team. 

Jan 12, 2017

Francis Ouellette

Génome Québec has appointed Francis Ouellette as VP of scientific affairs. In this role, Ouellette will lead efforts to define the company's vision and develop its scientific strategy. He will start in his new role Feb. 27. Prior to his work with Génome Québec, Ouellette served as associate director of the informatics and biocomputing platform and lead investigator at the Ontario Institute for Cancer Research. He also served as associate professor in the department of medical genetics at the University of British Columbia, director of the UBC Bioinformatics Center at the Michael Smith Laboratories, and coordinated the GenBank database for the US National Institutes of Health.

Jan 11, 2017

Mark Adams

Jackson Laboratory has appointed Mark Adams as director of microbial genomic services. In this role, Adams will enhance the organization's large scale microbiome initiatives. Adams joins Jackson Laboratory from the J. Craig Venter Institute, where he directed programs that characterized genomic changes in antibiotic resistance. He also founded the Institute for Genomic Research, co-founded Celera Genomics, and served as associate professor of genetics at Case Western Reserve University.

Jan 09, 2017

Haywood Cochrane

Acuamark Diagnostics announced Haywood Cochrane has joined its board of directors. He will transition from his current position as a member of the firm's advisory board. Cochrane is currently a director at Corium and vice chair of the board at the University of North Carolina, Chapel Hill. Previously, he was CEO of CHD Meridian and was president and CEO of Allied Clinical Labs. 

Jan 09, 2017

Randy Scott, Sean George

Invitae President and Chief Operating Officer Sean George will take over as CEO, effective immediately, the company announced. Current CEO Randy Scott will continue full time at Invitae serving as executive chairman of the board of directors. The changes come as the company is focused on driving global growth in genetic testing. Previously, George was a co-founder and CEO of genetic analysis startup Locus Development. Scott previously served as executive chairman at Genomic Health and chief operating officer at personal genomics firm Navigenics.

Jan 06, 2017

Philip Bourne

The National Institutes of Health announced today that Philip Bourne will be leaving his post as associate director for data science effective April 30, 2017. Bourne joined the NIH in 2014 to lead the Big Data to Knowledge program. He will join the University of Virginia, Charlottesville as Stephenson Chair of data science, director of the Data Science Institute, and professor in the Department of Biomedical Engineering. 

Jan 06, 2017

Christian Henry

Ginkgo Bioworks has appointed Christian Henry to its board of directors. Henry joins from Illumina, where he served as executive VP and chief commercial officer. While at Ilumina, he also served as CFO, general manager of Life Sciences, and senior VP of corporate development. Before Illumina, he served as CFO of Tickets.com and VP of finance of Affymetrix.

Jan 06, 2017

Ian Clark

Guardant Health has appointed Ian Clark to its board of directors. Clark joins Guardant Health from Genetech, where he served as CEO, and Roche, where he led North American commercial operations. He has also held leadership roles at Novartis, Sanofi, and Ivax.

Jan 06, 2017

Troy Cox, Michael Pellini

Foundation Medicine announced that it has appointed Troy Cox as CEO to succeed Michael Pellini, who has been appointed as chairman of the board of directors. Pellini replaces Alexis Borisy, who will continue to serve on the board. Cox joins Foundation Medicine from Roche-Genetech, where he led one of the largest oncology portfolios in the US. Before joining Genentech, he held leadership positions at UCB BioPharma, Sanofi-Aventis, and Schering-Plough.

Jan 05, 2017

Stephanie Hallam

Claritas Genomics has appointed Stephanie Hallam as VP of molecular diagnostics. Hallam joins Claritas from Good Start Genetics, where she served as VP of laboratory operations and medical director.. She has also served in management and leadership positions at Genzyme Genetics, Athena Diagnostics, the University of Utah, and the University of Colorado.

Jan 05, 2017

Michael Nemzek

MedGenome has appointed Michael Nemzek as chief commercial officer. Nemzek has held executive leadership positions in both public companies and private companies, including RareCyte, Affymetrix, and Velocity11. He also holds advanced degrees in chemistry from North Carolina State University and in management from the University of Maryland.

Jan 05, 2017

Brady Davis, John Ellithorpe

DNAnexus expands its executive leadership team by appointing Brady Davis as vice president of strategy and marketing and John Ellithorpe as chief product officer. Davis comes to DNAnexus from Illumina, where he identified investment and acquisition opportunities, developed strategic partnerships, and led global product marketing for informatics. Before his work at Illumina, he led business development, strategy, and innovation for Oracle's Health Science Global Business Unit. Ellithorpe joins Illumina from Vantiq, where he served as chief product officer. Before his work at Vantiq, he co-founded Model N, where he served as chief technology officer and chief product officer.

Jan 04, 2017

Cynthia Collins

Human Longevity has appointed Cynthia Collins as CEO. She replaces Craig Venter, who will remain at the company and serve as executive chairman of the board of directors. Collins comes to HLI from GE Healthcare, where she served as CEO and general manager for Cell Therapy and Purification and ANalysis Businesses. Before that she served as CEO of GE's Clarient Diagnostics. She has also held various executive positions at Genvec, Cellular Analysis Business Group, Sequoia Pharmaceuticals, and Clinical Microsensors (now Genmark).

Jan 04, 2017

Jan Verstreken

Hologic has appointed Jan Verstreken as regional president for Europe, Middle East and Africa (EMEA), and Canada. In this role, Verstreken will build growth strategies in the EMEA and Canadian markets. He most recently served as president for Asia Pacific. Before he joined Hologic, he had an impressive career at Teleflex.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.